ADC Therapeutics Q2 loss narrows; cuts 17% workforce

Adc Therapeutics

13/08/2026 12:38

Overview
Switzerland antibody drug conjugate developer's Q2 net loss narrowed, beating analyst expectations
Q2 net product revenue rose slightly year-over-year, driven by higher price
Company cut workforce by 17% to save $10 mln annually after completing key trials

Outlook
ADC Therapeutics anticipates growth starting in 2027
Company is assessing regulatory path for ZYNLONTA after FDA feedback on LOTIS-5 trial
ADC Therapeutics expects to provide an update on regulatory strategy and timing in the near future

Result Drivers
PRICE INCREASE - Q2 net product revenue rose year-over-year, driven by higher price
SHIFT IN PERSONNEL COSTS - Increase in cost of product sales was mainly due to personnel moving from R&D to commercial manufacturing
LOWER R&D SPENDING - R&D expense declined due to discontinued programs and completion of IND-enabling activities

Company press release: ID:nPn33QwvTa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
Beat
$16.57 mln
$33.96 mln (5 Analysts)
Q2 Income from Operations
Miss
-$25.41 mln
-$24.36 mln (5 Analysts)
Q2 Loss Per Basic Share
 
$0.11
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for ADC Therapeutics SA is $2.50, about 103.3% above its August 12 closing price of $1.23

Reuters Recommended Reads
Aug 12 - Sutro Biopharma Q2 revenue misses estimates, posts wider loss
Aug 12 - Switzerland's Pharvaris Q2 loss narrows, cash rises to €318 mln
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)